Assessment of the teratogenic profile of antiemetics in early pregnancy [Evaluación del perfil teratogénico de antieméticos en la gestación temprana]
DOI:
https://doi.org/10.62574/3s67vp78Keywords:
metoclopramide, first trimester of pregnancy, congenital anomaliesAbstract
Objective: To analyse the evaluation of the teratogenic profile of antiemetics in early pregnancy. Method: systematic review. Results and conclusion: The available scientific evidence supports that metoclopramide can be considered safe for the treatment of nausea and vomiting during the first trimester of pregnancy. Large cohort studies and prospective follow-ups have not demonstrated an association with major congenital malformations or significant adverse effects on foetal development. Therefore, metoclopramide is a valid therapeutic option when symptomatic control is necessary and conservative measures have proven insufficient.
Downloads
References
Pasternak B, Svanström H, Mølgaard-Nielsen D, Melbye M, Hviid A. Use of metoclopramide in pregnancy and risk of major congenital malformations: a nationwide cohort study. JAMA. 2013;310(14):1601-1611.
Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Uziel E, et al. The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med. 2009;360(24):2528-2535.
Koren G, Clark S, Hankins GDV, Caritis SN, Miodovnik M, Umans JG, et al. Effectiveness of doxylamine-pyridoxine for nausea and vomiting of pregnancy: a randomized, placebo-controlled trial. Am J Obstet Gynecol. 2010;203(6):571.e1-7.
McKenna DA, McIntire DD, Sheffield JS, Hollier LM, Wendel GD Jr. Metoclopramide use during pregnancy: a prospective observational study. Am J Perinatol. 2005;22(1):7-10.
Larsen H, Nielsen GL, Bendsen J, Flint C, Olsen J. Birth outcome following use of metoclopramide in pregnancy. Br J Clin Pharmacol. 2000;49(3):264-268.
Berkovitch M, Mazzota P, Greenberg R, Addis A, Schuler-Faccini L, Da Silva Dal Pizzol T, et al. Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. Am J Perinatol. 2002;19(4):203-207.
Einarson A, Maltepe C, Navioz Y, Kennedy D, Koren G. The safety of metoclopramide use in the first trimester of pregnancy: a prospective controlled trial. Am J Obstet Gynecol. 2004;190(3):654-657.
Sánchez J. Efectos extrapiramidales por metoclopramida en embarazo y recién nacido. Rev Salud Bosque. 2015;5(1):63-66.
Bailon Muñoz E. La metoclopramida es un fármaco seguro para tratar las náuseas y los vómitos en el primer trimestre del embarazo. FMC. 2009;16(9):529-531.
Izbizky G. La metoclopramida no se asocia a resultados obstétricos adversos. Evidencia Actualización en la Práctica Ambulatoria. 2014;17(1).
Schaefer C, Peters P, Miller RK. Drugs during pregnancy and lactation: treatment options and risk assessment. 3rd ed. London: Academic Press; 2015.
Magee LA, Mazzotta P, Koren G. Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obstet Gynecol. 2002;186(5 Suppl Understanding):S256-S261.
Einarson A, Maltepe C, Boskovic R, Koren G. Treatment of nausea and vomiting in pregnancy: an updated algorithm. Can Fam Physician. 2007;53(12):2109-2111.
Carstairs SD. Ondansetron use in pregnancy and birth defects: a systematic review. Obstet Gynecol. 2016;127(5):878-883.
Wang Y, Smolinski NE, Thai TN, et al. Common teratogenic medication exposures-a population-based study of pregnancies in the United States. Am J Obstet Gynecol MFM. 2024;6(1):101245. doi:10.1016/j.ajogmf.2023.101245
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Jorge Emiliano Sagnai-Saltos, Silvia del Pilar Nuñez-Arroba, Gabriela Lizeth Mena-Zambrano (Autor/a)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
